Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Trade Desk Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.85 (market cap $29.60B), while Trade Desk Inc trades at $13.38 (market cap $6.37B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.6× Trade Desk Inc's market cap. Which is the better fit depends on your goals.
| ALNY | TTD | |
|---|---|---|
Market Cap | $29.60B | $6.37B |
Sector | Health | Technology |
52-Week High | $491.22 | $55.36 |
52-Week Low | $205.48 | $13.39 |
Enterprise Value | $27.56B | $5.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
The Trade Desk (TTD) stock trades at $13.33, near its 52-week low, reflecting a bearish technical trend with recent earnings misses and a 12% revenue decline guidance for Q3 2026. Despite strong profitability margins, the company faces execution gaps and competitive pressures in the ad-tech sector, leading to significant analyst downgrades and negative media sentiment.
Outlook remains cautious with high risk; potential exists if operational improvements reverse recent declines, but near-term headwinds from weak guidance and macroeconomic pressures suggest continued volatility. The stock's valuation appears reasonable, but investor confidence hinges on a demonstrated turnaround in revenue growth and execution stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
